REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
21/07/2025
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Snapshot rápido
QIAGEN - SAMPLE TO OUTCOME
ST13
US500000079264394Classe
Pedido
Registro
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Tipo de processo
Eventos registrados
Atualização mais recente
Classificação
Tipo de marca
Classes Nice
Data de depósito
Data de registro
Data de expiração
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
Última transação
Escritório responsável
Código da situação
Cadastro oficial
Código do desenho
Tipo de titular
Localização do titular
Examinador
Unidade examinadora
Localização atual
Titulares
Representantes
Keith A. Weltsch Scully, Scott, Murphy & Presser, P.C.
Classes Nice
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable and recorded computer software for data and document management, medical teaching; downloadable and recorded computer software and related downloadable databases for use in preparing and managing nucleic acid and protein assay analysis and for managing quality control, validation, interpretation, reporting, clinical decision support, data management, integration with medical records, physician portals, laboratory networking, professional healthcare and trial matching services all related to molecular and genomic analysis; downloadable and recorded computer software, namely, evidence-based decision support software used as an aid in the interpretation of variants observed in genomic sequencing data; downloadable and recorded computer software for evaluation of genomic variants in the context of software for searching and allocating published biomedical literature, professional association guidelines, publicly available databases and annotations, drug labels, and/or clinical-trials; downloadable and recorded computer software for preparing, interpretation and managing of bioinformatics analyses, optionally combined with data management, graphical viewing and output options; downloadable and recorded computer programs and software for biological data mining; downloadable and recorded computer programs and software for developing bioinformatics database for others; bio-chips for research or scientific purposes; DNA-chips; RNA-chips; next-generation sequencing (NGS) data processor; bioinformatics data processor; computer hardware and downloadable and recorded computer software for collecting, storing, analyzing, visualizing, and interpreting bioinformatics, genomics, and phenomics data sets; computer hardware and downloadable and recorded computer software for the monitoring of pathogens; downloadable computer databases for bioinformatics, genomics, phenomics, microbiome, metagenomics, organism-and -pathogen-specific genotype records, and organism and pathogen-specific phenotype information; downloadable and recorded computer software for use in the integration, analysis and visualization of biomedically relevant information allowing users to explore compound, target, assay, biological pathway and disease information; downloadable and recorded computer software and databases for the analysis of genomes, exomes, targeted amplicons, transcriptomes, and epigenetic NGS sequencing data; downloadable and recorded computer software, software development tools, and visualization software modules, for analysis, discovery, verification, and validation of disease biomarkers
Classe 10
Medical diagnostic testing instruments for processing and analysis of genetic samples primarily for single-cell genomic, transcriptomic, or proteomic analysis; medical and diagnostic apparatus for testing DNA and RNA samples, using gene expression tests, gene expression profiling assays, genetic information and data, protein biomarkers, clinical data, and/or demographic information; testing apparatus for medical purposes for testing DNA and RNA samples sold as a unit with downloadable bioinformatics and machine learning algorithm software and medical data software to support treatment decisions; medical testing apparatus for testing DNA and RNA samples and quantifying biomarker levels and relative expression of host response genes; medical apparatus and instruments for detecting tumor cancer, heredity and genetic diseases; medical testing apparatus for samples of body fluids, tissue and organs; genome machine for medical purposes, namely, apparatus for DNA and RNA medical testing; diagnostic apparatus for the detection of cancer, genetic or heredity diseases
Classe 42
Providing temporary use of online non-downloadable software for use in collecting, organizing and managing data on bioinformatics, genomics, phenomics, microbiome, and metagenomics applications; hosting of computer databases featuring information relating to bioinformatics, genomics, phenomics, microbiome, metagenomics, organism- and pathogenspecific genotype records, and organism and pathogen-specific phenotype information; consulting relating to computer programming for acquiring, creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients; providing an online, non-downloadable computer software platform for purposes of storing and providing information about an individual's disease profile and genomic changes to enable physicians and healthcare professionals to optimize treatment in clinical practice; providing temporary use of on-line nondownloadable software and applications for genome analysis, developing personal treatment strategies for patients with diagnosed cancer and other diseases or disorders; conducting early evaluations in the field of new pharmaceuticals; consulting services in the fields of biotechnology and pharmaceutical research; providing information about medical and scientific research in the field of bioinformatics to enable physicians and healthcare professionals to optimize treatment in clinical practice; computer programming services for medical reporting, namely, for creating, sharing, managing, mining, analyzing, visualizing, interpreting and applying genomics and phenomics records; scientific research services, namely, providing information relating to research in the field of specific molecular and genomic sciences for analytical and clinical purposes, for the treatment of cancer and other diseases and disorders and for individuals' responses to drug treatments; providing scientific advice in the fields of cancer biology, cancer treatment, pharmaceutical side effects, genomics, cancer medicine and translational medicine; providing scientific analysis in the field of next generation sequencing (NGS), namely, the analysis and interpretation of genomic data obtained from patients with cancer and other diseases and disorders
Classe 44
Providing medical information and medical advice in the fields of retrieval, integration, correlation, analysis and interpretation of genomic data, sequencing data and molecular data, diseases, biomarkers, drug protocols, drug interactions, clinical profiles, and medical and health information, records or data and patient-specific data, molecular test results, clinical trial data; medical consulting services in the fields of health, medical care, biotechnology, bioinformatics, life sciences, pharmaceuticals and medicine; providing medical information in the fields of health, healthcare, life sciences, biotechnology, pharmaceuticals and pharmaceutical safety, bioinformatics, and genetic testing for medical purposes; medical consulting services with respect to the treatment and diagnosis of individuals; providing medical information on drug safety and drug compatibility in relation to therapy and the treatment of individuals; medical consulting services in the fields of diagnostics and patient treatment and treatment protocols; medical consulting services in the field of genomics and biological sequence processing and analysis for medical diagnosis and treatment purposes; providing medical information for the purposes of medical diagnosis and treatment in the field of molecular genetics; identification and testing of DNA samples for health care purposes; health care services, namely, medical genomics and data science consultancy to provide optimal health and disease prevention or treatment to patients; providing health information relating to genetics and diagnostics via the Internet; bioinformatics analysis for medical diagnostic and personalized treatment purposes; nucleic acid analysis and screening for medical diagnostic and treatment purposes
Histórico de despachos e eventos da marca no USPTO.
27 publicações encontradas
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
21/07/2025
FINAL DECISION TRANSACTION PROCESSED BY IB
05/12/2020
FINAL DISPOSITION NOTICE SENT TO IB
12/11/2020
FINAL DISPOSITION PROCESSED
12/11/2020
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/10/2020
REGISTERED-PRINCIPAL REGISTER
21/07/2020
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/05/2020
PUBLISHED FOR OPPOSITION
05/05/2020
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/04/2020
ASSIGNED TO LIE
02/04/2020
APPROVED FOR PUB - PRINCIPAL REGISTER
25/03/2020
EXAMINER'S AMENDMENT ENTERED
25/03/2020
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
25/03/2020
EXAMINERS AMENDMENT E-MAILED
25/03/2020
EXAMINERS AMENDMENT -WRITTEN
25/03/2020
TEAS/EMAIL CORRESPONDENCE ENTERED
05/03/2020
CORRESPONDENCE RECEIVED IN LAW OFFICE
04/03/2020
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/03/2020
REFUSAL PROCESSED BY IB
28/09/2019
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
06/09/2019
REFUSAL PROCESSED BY MPU
06/09/2019
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
14/08/2019
NON-FINAL ACTION WRITTEN
13/08/2019
APPLICATION FILING RECEIPT MAILED
13/08/2019
ASSIGNED TO EXAMINER
09/08/2019
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
09/08/2019
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/08/2019
Proteção contínua da sua marca
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.